Inlyta
Kidney Cancer on MedicineNet »
"The kidneys
The kidneys are a pair of organs on either side of the spine in the lower abdomen. Each kidney is about the size of a fist. Attached to the top of each kidney is an adrenal gland. "...
Read the entire article on MedicineNet »
© 1999-2013 MedicineNet, Inc All right reserved
Inlyta
Inlyta Side Effects Center
Medical Editor: Melissa Conrad Stöppler, MD
Inlyta (axitinib) is a prescription medication indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy for this type of cancer. The most common side effects observed in greater than 20 percent of patients were diarrhea, high blood pressure (hypertension), fatigue, decreased appetite, nausea, loss of voice (dysphonia), hand-foot syndrome (palmar-plantar erythrodysesthesia), weight loss, vomiting, weakness (asthenia) and constipation. Some patients who took Inlyta experienced bleeding problems, which in some cases were fatal.
Inlyta comes in 1 mg and 5 mg strengths. The starting dose is 5 mg taken orally twice daily, approximately 12 hours, with a full glass or water, with or without food.
Inlyta can be harmful to unborn children causing severe birth defects or death. Women who can become pregnant should evaluate the risks of using Erivedge with their doctors.. It is not known if Inlyta passes into breast milk. The patient and the doctor should decide whether or not to take Inlyta. Nursing mothers should not do both.
Our Inlyta Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Inlyta FDA Prescribing Information: Side Effects
(Adverse Reactions)
SIDE EFFECTS
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of INLYTA has been evaluated in 715 patients in monotherapy studies, which included 537 patients with advanced RCC. The data described reflect exposure to INLYTA in 359 patients with advanced RCC who participated in a randomized clinical study versus sorafenib [see Clinical Studies].
The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label [see WARNINGS AND PRECAUTIONS]: hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, and fetal development.
Clinical Trials Experience
The median duration of treatment was 6.4 months (range 0.03 to 22.0) for patients who received INLYTA and 5.0 months (range 0.03 to 20.1) for patients who received sorafenib. Dose modifications or temporary delay of treatment due to an adverse reaction occurred in 199/359 patients (55%) receiving INLYTA and 220/355 patients (62%) receiving sorafenib. Permanent discontinuation due to an adverse reaction occurred in 34/359 patients (9%) receiving INLYTA and 46/355 patients (13%) receiving sorafenib.
The most common ( ≥ 20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation. Table 1 presents adverse reactions reported in ≥ 10% patients who received INLYTA or sorafenib.
Table 1: Adverse Reactions Occurring in ≥ 10% of
Patients Who Received INLYTA or Sorafenib
| Adverse Reactiona | INLYTA (N=359) |
Sorafenib (N=355) |
||
| All Gradesb % | Grade 3/4 % | All Gradesb % | Grade 3/4 % | |
| Diarrhea | 55 | 11 | 53 | 7 |
| Hypertension | 40 | 16 | 29 | 11 |
| Fatigue | 39 | 11 | 32 | 5 |
| Decreased appetite | 34 | 5 | 29 | 4 |
| Nausea | 32 | 3 | 22 | 1 |
| Dysphonia | 31 | 0 | 14 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | 27 | 5 | 51 | 16 |
| Weight decreased | 25 | 2 | 21 | 1 |
| Vomiting | 24 | 3 | 17 | 1 |
| Asthenia | 21 | 5 | 14 | 3 |
| Constipation | 20 | 1 | 20 | 1 |
| Hypothyroidism | 19 | < 1 | 8 | 0 |
| Cough | 15 | 1 | 17 | 1 |
| Mucosal inflammation | 15 | 1 | 12 | 1 |
| Arthralgia | 15 | 2 | 11 | 1 |
| Stomatitis | 15 | 1 | 12 | < 1 |
| Dyspnea | 15 | 3 | 12 | 3 |
| Abdominal pain | 14 | 2 | 11 | 1 |
| Headache | 14 | 1 | 11 | 0 |
| Pain in extremity | 13 | 1 | 14 | 1 |
| Rash | 13 | < 1 | 32 | 4 |
| Proteinuria | 11 | 3 | 7 | 2 |
| Dysgeusia | 11 | 0 | 8 | 0 |
| Dry skin | 10 | 0 | 11 | 0 |
| Dyspepsia | 10 | 0 | 2 | 0 |
| Pruritus | 7 | 0 | 12 | 0 |
| Alopecia | 4 | 0 | 32 | 0 |
| Erythema | 2 | 0 | 10 | < 1 |
| aPercentages are treatment-emergent, all-causality
events bNational Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 |
||||
Selected adverse reactions (all grades) that were reported in < 10% of patients treated with INLYTA included dizziness (9%), upper abdominal pain (8%), myalgia (7%), dehydration (6%), epistaxis (6%), anemia (4%), hemorrhoids (4%), hematuria (3%), tinnitus (3%), lipase increased (3%), pulmonary embolism (2%), rectal hemorrhage (2%), hemoptysis (2%), deep vein thrombosis (1%), retinal-vein occlusion/thrombosis (1%), polycythemia (1%), transient ischemic attack (1%), and RPLS ( < 1%).
Table 2 presents the most common laboratory abnormalities reported in ≥ 10% patients who received INLYTA or sorafenib.
Table 2: Laboratory Abnormalities Occurring in
≥ 10% of Patients Who Received INLYTA or Sorafenib
| Laboratory Abnormality | N | INLYTA | N | Sorafenib | ||
| All Gradesa % | Grade 3/4 % | All Grades a % | Grade 3/4 % | |||
| Hematology | ||||||
| Hemoglobin decreased | 320 | 35 | < 1 | 316 | 52 | 4 |
| Lymphocytes (absolute) decreased | 317 | 33 | 3 | 309 | 36 | 4 |
| Platelets decreased | 312 | 15 | < 1 | 310 | 14 | 0 |
| White blood cells decreased | 320 | 11 | 0 | 315 | 16 | < 1 |
| Chemistry | ||||||
| Creatinine increased | 336 | 55 | 0 | 318 | 41 | < 1 |
| Bicarbonate decreased | 314 | 44 | < 1 | 291 | 43 | 0 |
| Hypocalcemia | 336 | 39 | 1 | 319 | 59 | 2 |
| ALP increased | 336 | 30 | 1 | 319 | 34 | 1 |
| Hyperglycemia | 336 | 28 | 2 | 319 | 23 | 2 |
| Lipase increased | 338 | 27 | 5 | 319 | 46 | 15 |
| Amylase increased | 338 | 25 | 2 | 319 | 33 | 2 |
| ALT increased | 331 | 22 | < 1 | 313 | 22 | 2 |
| AST increased | 331 | 20 | < 1 | 311 | 25 | 1 |
| Hypernatremia | 338 | 17 | 1 | 319 | 13 | 1 |
| Hypoalbuminemia | 337 | 15 | < 1 | 319 | 18 | 1 |
| Hyperkalemia | 333 | 15 | 3 | 314 | 10 | 3 |
| Hypoglycemia | 336 | 11 | < 1 | 319 | 8 | < 1 |
| Hyponatremia | 338 | 13 | 4 | 319 | 11 | 2 |
| Hypophosphatemia | 336 | 13 | 2 | 318 | 49 | 16 |
| aNational Cancer Institute Common Terminology
Criteria for Adverse Events, Version 3.0 ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase |
||||||
Selected laboratory abnormalities (all grades) that were reported in < 10% of patients treated with INLYTA included hemoglobin increased (above the upper limit of normal) (9% for INLYTA versus 1% for sorafenib).
Read the entire FDA prescribing information for Inlyta (Axitinib) »
Additional Inlyta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
